Filing Flows › Abbott Laboratories (ABT) › Q3 2025
Abbott Laboratories (ABT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 29, 2025
Abbott Laboratories (ABT) reported revenue of $11.4B for the third quarter 2025 (Q3 2025), +7% from a year earlier and +2% from the quarter before. Operating margin was 18.1%, net earnings $1.6B (14.5% of revenue).
Abbott Laboratories, Q3 2025: revenue $11.4B (+7% year over year), operating margin 18.1%, net earnings $1.6B, operating cash flow $2.8B. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.4B | +2% | +7% |
| Operating profit | $2.1B | +0.2% | +11% |
| Net earnings | $1.6B | -8% | -0.1% |
| Operating cash flow | $2.8B | +36% | +3% |
| Free cash flow | $2.3B | +48% | +7% |
What changed
Revenue was $11.4B in Q3 2025, up 7% year over year and up 2% from the previous quarter.
Operating profit was $2.1B, a 18.1% margin (up 0.6 points year over year). Of the extra revenue versus a year earlier, 27% reached operating profit, above the 17% margin then. Total costs grew 6% against revenue growth of 7%. Net earnings were $1.6B, roughly flat year over year. The effective tax rate was 24.6%.
Operating cash flow was $2.8B (up 3% year over year), 170% of net earnings. Non-cash charges added back $0.79B of depreciation and amortization and $0.12B of share-based compensation. Working capital and other items added $0.23B. Capital expenditures of $0.50B left free cash flow of $2.3B.
Questions
What was Abbott Laboratories' revenue in the third quarter 2025?
Abbott Laboratories (ABT) reported revenue of $11.4B for the third quarter 2025 (Q3 2025), +7% from a year earlier and +2% from the quarter before.
Was Abbott Laboratories profitable in the third quarter 2025?
Operating profit was $2.1B (18.1% of revenue) and net earnings $1.6B.